Ubs Group Ag Dia Medica Therapeutics Inc. Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,769 shares of DMAC stock, worth $10,012. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,769
Previous 12,739
86.11%
Holding current value
$10,012
Previous $53,000
83.02%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding DMAC
# of Institutions
49Shares Held
5.27MCall Options Held
8.9KPut Options Held
200-
Vanguard Group Inc Valley Forge, PA1.24MShares$7.03 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$4.75 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX515KShares$2.91 Million6.41% of portfolio
-
Bleichroeder LP New York, NY382KShares$2.16 Million0.63% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA375KShares$2.12 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $150M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...